In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible Enterococcus faecium

  • Michael P Lorenzo
    Department of Pharmacy, Rhode Island Hospital, Providence, RI, USA
  • James M Kidd
    Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA
  • Stephen G Jenkins
    Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA
  • David P Nicolau
    Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA
  • Seth T Housman
    Western New England University College of Pharmacy and Health Sciences, Springfield, MA, USA

説明

<jats:title>Abstract</jats:title><jats:sec><jats:title>Objectives</jats:title><jats:p>To assess activity of the combination of ceftriaxone and ampicillin against clinical isolates of ampicillin-susceptible Enterococcus faecium.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Ampicillin-susceptible E. faecium (n = 29) and Enterococcus faecalis (n = 10) collected from locations in the USA and France were used for this analysis. Susceptibility testing was performed by gradient diffusion strip (GDS) and broth microdilution (BMD). Synergy with the combination of ceftriaxone and ampicillin was assessed in all isolates using GDS crossing and double disc diffusion methods. Selected isolates (nine E. faecium and three E. faecalis) were assessed for synergy in time–kill studies using ampicillin alone and in combination with ceftriaxone.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In isolates of E. faecium, the median (range) ampicillin MIC by BMD was 0.5 (0.25–4) mg/L and by GDS it was 2 (1–8)  mg/L. In E. faecalis, the median (range) ampicillin MIC by BMD was 0.5 (0.5–1) mg/L and by GDS it was 2 (0.75–3) mg/L. A total of 24/29 (82.8%) isolates of E. faecium displayed synergy by GDS and 22/29 (75.9%) by double disc diffusion. Seven of 10 (70%) isolates of E. faecalis displayed synergy by GDS and 4/10 (40%) by double disc diffusion. Time–kill studies found synergy in 3/9 (33.3%) E. faecium and 3/3 (100%) E. faecalis.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>In contrast to the demonstrated synergy in time–kill models of ceftriaxone and ampicillin for E. faecalis, this combination does not appear to provide uniform synergy in E. faecium. Antagonism was not observed. Clinical correlation is necessary and caution should be used when considering ampicillin and ceftriaxone for the treatment of infections caused by ampicillin-susceptible E. faecium.</jats:p></jats:sec>

収録刊行物

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ